SynthesisBMC infectious diseases2026
Visceral leishmaniasis elimination in Ethiopia: insights into epidemiology, transmission, treatment access, and outcome - a systematic review and meta-analysis.
Synthesis in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
Abstract
backgroundEthiopia is a high-burden country for visceral leishmaniasis (VL) and has committed to regional elimination by 2030. Current evidence on disease epidemiology, transmission dynamics, treatment access, and clinical outcomes is essential for transitioning from control to elimination efforts. This systematic review and meta-analysis synthesizes the available literature on the prevalence, associated risk factors, accessibility and effectiveness of treatment, transmission patterns, clinical outcomes, and ecological factors influencing VL distribution, including vector habitats, climate conditions, and land-use patterns.
methodsLiterature searches were conducted using PubMed, SCOPUS, EMBASE, CINAHL, HINARI, ScienceDirect, Google Scholar, and grey literature sources following PRISMA 2020 reporting guidelines. Study quality was assessed using the Joanna Briggs Institute (JBI) tools. Random-effects meta-analyses were used to estimate pooled prevalence and associated risk factors. In addition to systematic review and meta-analysis, we conducted a descriptive analysis of WHO surveillance data to assess the trend of caseload, treatment access, and cured treatment outcomes using R software version 4.5.1 and ArcGIS version 10.7, respectively.
resultsThe study revealed that pooled VL prevalence (32 studies, 103,962 participants) was 15.29% (95% CI: 9.25–22.51) in institution-based and 10.38% (95% CI: 5.38–16.74) in community-based settings, with substantial variation according to detection methods employed. Male sex (OR = 1.86), sleeping outdoors (OR = 2.85) or on the ground (OR = 1.92), and travel to endemic areas (OR = 3.99) were significantly associated with VL infection. Family history of VL (OR = 2.27) and rural residence (OR = 2.27) increased VL risk substantially. Environmental factors, including proximity to termite mounds (OR = 3.60), presence of acacia trees (OR = 3.75), and hyraxes near dwellings (OR = 1.90), were significantly associated with increased VL risk. Spatial analysis revealed persistent VL transmission with intermittent outbreaks concentrated in high and very high VL-risk areas, primarily in the Kolla and Lower Kolla agroecological zones. Geographic inequities in treatment access were evident, with higher case numbers treated in northern endemic foci and increasing trends in southern and eastern foci. The sodium stibogluconate and paromomycin combination regimen demonstrated high cure rates.
conclusionVisceral leishmaniasis (VL) in Ethiopia shows heterogeneous prevalence, highest with leishmanin skin tests. Male sex, farming, family history, outdoor sleeping, and proximity to termite mounds, acacia trees, and domestic animals were major risk factors. VL distribution aligned with sandfly vectors, particularly Phlebotomus orientalis, across lowlands and transitional highlands. National treatment data (2017–2024) showed generally favorable outcomes, highlighting the need for targeted elimination strategies based on local prevalence, risk factors, and effective case management. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.